Verastem Reported Positive Drug Trial Results

The pharmaceutical company announced promising trial data and a $250 million stock offering.

Updated on Oct. 14, 2026 in Cancer

Isometric editorial illustration of a glass beaker containing a crystalline molecular structure, representing a pharmaceutical cancer drug advancement. — Verastem announced positive clinical trial results for its cancer inhibitor VS-7375 and priced a $250 million public share offering. AI Illustration. Upload story photo >

Live Poll

Is now a good time for individual investors to buy shares in speculative biotech companies?

Verastem reported positive Phase 1/2 clinical trial results for its oral drug VS-7375, which targets cancers with the KRAS G12D mutation. Alongside these results, the company priced a $250 million public offering of 30.94 million shares.

Why it matters

The capital raised from the public offering will fund the ongoing development of VS-7375 and support general corporate operations. These funds are intended to prepare the company for the advancement of its clinical pipeline.

In Phase 1/2 trials, 41% of pancreatic cancer patients at 900 mg and 43% of lung cancer patients at 600 mg showed confirmed tumor responses. Pancreatic cancer patients additionally achieved an 86% disease control rate.

The players

Verastem

This is a biopharmaceutical company focused on developing small molecule drugs for cancer treatment.

Michael P. Bailey

He is the incoming CEO of Verastem who is set to assume his leadership role at the start of 2027.

Daniel Paterson

He is the outgoing CEO of Verastem who will transition to a role as a board adviser.

The details

The drug VS-7375 functions as an oral inhibitor targeting the KRAS G12D mutated protein. Verastem priced its latest offering at $8 per share, marking a 7.4% premium over the stock closing price observed on October 13, 2026.

June 2026 marked the reported date for $136.4 million in company cash and investments.
October 13, 2026, was the reference date for the stock closing price premium.
October 14, 2026, saw the company report trial results and launch its public offering.
The end of 2026 is the scheduled window for initiating a Phase 3 pancreatic cancer trial.
January 1, 2027, marks the start date for Michael P. Bailey as the new CEO.

The Big Picture

This development is part of the ongoing clinical evaluation of KRAS-targeted cancer therapies which follows years of research into difficult-to-treat genetic mutations. It marks a significant milestone in the evolution of precision medicine for specific protein mutations.

Patients with advanced cancers carrying the KRAS G12D mutation may eventually gain access to a new oral treatment option pending successful Phase 3 trial results. The financial stability provided by the recent capital raise supports the continued testing and potential future availability of this drug.

The takeaway

The successful trial data and secondary stock offering provide Verastem with the necessary runway to advance its clinical pipeline into Phase 3 testing. Investors and patients should monitor the upcoming 2026 launch of the late-stage trial for further confirmation of drug efficacy.

What happens next

Verastem is scheduled to initiate a Phase 3 trial for its pancreatic cancer treatment by the end of 2026, with leadership changes taking effect on January 1, 2027.